NCT01032200 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity. Armodafinil: Given orally
- id
- FG000
- title
- Arm I - Armodafinil
- description
- Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity. placebo: Given orally
- id
- FG001
- title
- Arm II - Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 3
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 2
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- type
- Progression
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Multiple
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 26
- group Id
- FG001
- num Subjects
- 28
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 22
- group Id
- FG001
- num Subjects
- 21
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 7
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity. Armodafinil: Given orally
- id
- FG000
- title
- Arm I - Armodafinil
- description
- Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity. placebo: Given orally
- id
- FG001
- title
- Arm II - Placebo
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 3
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 2
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- type
- Progression
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Multiple
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 26
- group Id
- FG001
- num Subjects
- 28
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 22
- group Id
- FG001
- num Subjects
- 21
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 7
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle